Citigroup Maintains Buy on Haemonetics, Raises Price Target to $149
Benzinga Newsdesk 23 hours ago
Analyst RatingsNewsPrice Target
Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:HAE) with a Buy and raises the price target from $123 to $149.
Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:HAE) with a Buy and raises the price target from $123 to $149.